We are live on ! Find out more
NAGE

Niagen Bioscience
NAGE

42 hedge funds and large institutions have $14.2M invested in Niagen Bioscience in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

4% less capital invested

Capital invested by funds: $14.7M → $14.2M (-$555K)

1.51% less ownership

Funds ownership: 8.36% → 6.85% (-1.5%)

9% less funds holding

Funds holding: 46 → 42 (-4)

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

Holders
42
Holders Change
-4
Holders Change %
-8.7%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
12
Reduced
11
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$311K
2
VF
Virtu Financial
New York
+$231K
3
PHS
Pekin Hardy Strauss
Illinois
+$128K
4
TDC
Thompson Davis & Co
Virginia
+$109K
5
UBS Group
UBS Group
Switzerland
+$79.3K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$698K
2
PP
Paloma Partners
Connecticut
-$406K
3
ECM
Element Capital Management
New York
-$380K
4
LP
LMR Partners
United Kingdom
-$347K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$249K
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
26
MAI Capital Management
Ohio
$46K – – –
Bank of America
27
Bank of America
North Carolina
$20K -$41.9K -11,470 -71%
OIA
28
OneDigital Investment Advisors
Kansas
$17K – – –
Group One Trading
29
Group One Trading
Illinois
$17K +$14.6K +4,000 New
PCA
30
Peddock Capital Advisors
Massachusetts
$15K – – –
PFO
31
Pathstone Family Office
New Jersey
$13K – – –
Morgan Stanley
32
Morgan Stanley
New York
$9K +$2.18K +596 +40%
IWM
33
IHT Wealth Management
Illinois
$8K – – –
ASN
34
Advisory Services Network
Georgia
$6K +$5.48K +1,500 New
HS
35
Horan Securities
United States
$5K – – –
TRCT
36
Tower Research Capital (TRC)
New York
$5K +$1.78K +487 +72%
AA
37
AlphaMark Advisors
Kentucky
$3K – – –
MAM
38
Meeder Asset Management
Ohio
$3K +$113 +31 +5%
RE
39
RBC Europe
United Kingdom
$714 +$607 +166 New
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$34 – – –
Goldman Sachs
41
Goldman Sachs
New York
– -$698K -182,633 Closed
PP
42
Paloma Partners
Connecticut
– -$406K -106,250 Closed
LP
43
LMR Partners
United Kingdom
– -$347K -90,841 Closed
CS
44
Credit Suisse
Switzerland
– -$211K -55,381 Closed
Deutsche Bank
45
Deutsche Bank
Germany
– -$176K -48,055 -100%
BCM
46
BlueCrest Capital Management
Jersey
– -$91K -23,708 Closed
PG
47
PEAK6 Group
Illinois
– -$53K -13,874 Closed
RJFSA
48
Raymond James Financial Services Advisors
Florida
– -$39K -10,334 Closed
AIM
49
Acrospire Investment Management
Illinois
– -$17K -4,513 Closed
AWM
50
Avior Wealth Management
Nebraska
– -$8K -2,000 Closed
1
2
3

NAGE Hedge Fund Activity: Q3 2017 in Review

42 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2017, worth a combined $14.2M — down 3.8% from $14.7M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NAGE and 9 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Vanguard Group, adding an estimated $311K. The largest seller was Goldman Sachs, exiting entirely with an estimated $698K sold.

  • 42 institutional investors held Niagen Bioscience (NAGE) as of Q3 2017, down from 46 in Q2 2017.
  • Funds reported $14.2M of Niagen Bioscience stock for Q3 2017, down 3.8% quarter-over-quarter.
  • 9 funds opened new Niagen Bioscience positions in Q3 2017 and 12 closed out, a net change of -3 holders.
  • The largest Niagen Bioscience buyer in Q3 2017 was Vanguard Group, an estimated $311K added.
  • The largest Niagen Bioscience seller in Q3 2017 was Goldman Sachs, an estimated $698K sold.

Based on aggregated 13F filings for Q3 2017.